TECH
Novacyt ALNOV Graham Mullis, CEO of the Novacyt Group, commented:
“Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new partnerships. Throughout the pandemic, the demand for NHS testing has remained a key priority for the company and the award of the contract under the National PHE Microbiology Framework is a testament to our continued commitment.
“We believe that our long-term strategy also supports the growth of Novacyt after COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the opportunity for COVID-19 testing, but also ensure that we are well positioned, along with technologies and partners, for sustainable growth. beyond COVID-19. We therefore believe that Novacyt is well placed to continue to develop its business transformation. "
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
About the Novacyt Group
The Novacyt Group is an international diagnostic company generating a growing portfolio of in vitro and molecular diagnostic tests. Its main strengths lie in the development, marketing, design and manufacture of diagnostic products. The main business units of the Company include the Primerdesign and Lab21 products, providing a wide range of high quality assays and reagents worldwide. The Group directly serves the microbiology, hematology and serology markets as well as its global partners, including large companies.
AMZN Consolidation ZonesAs they say... the more extensive the consolidation zone, the bigger the breakout/leg-up tends to be.
After staying in a very tight range for almost a year and a half, I believe AMZN is about ready to breakout after Q4 earnings are released following the holiday season.
Just my personal opinion, not investment advice.
ABNB Large Base Formation We're witnessing some relatively volatile price action after ABNB reported solid Q3 earnings. I believe ABNB is a disruptive play on innovation that everyone should hold in their LT portfolio, with accelerating EPS and increasing market share within the hospitality industry.
Technically speaking, the price action for ABNB keeps returning to its broad base on the daily timeframe and bouncing every time. I like watching this base for solid entry points/DCA on my position.
Just my personal opinion, not investment advice.
Long NVDA HereBeautiful consolidation is occurring here with $NVDA after the Fed clarified tapering decisions today.
Nice bounce off the 0.618 Fib level with RSI curling back up as well after hitting lows on the daily timeframe. It appears to be a great entry if NVDA can clear the 0.786 Fib level next.
Just my personal opinion, not investment advice!